Search results for "PARTICLES"

showing 10 items of 8085 documents

Mesoporous inorganic nanoscale particles for drug adsorption and controlled release.

2018

The review provides an overview of the mesoporous inorganic particles employed as drug delivery systems for controlled and sustained release of drugs. We have classified promising nanomaterials for drug delivery on the basis of their natural or synthetic origin. Nanoclays are available in different morphologies (nanotubes, nanoplates and nanofibers) and they are typically available at low cost from natural resources. The surface chemistry of nanoclays is versatile for targeted modifications to control loading and release properties. Synthetic nanomaterials (imogolite, laponite and mesoporous silica) present the advantages of well-established purity and availability with size features that …

Drug CarriersMaterials sciencePharmaceutical ScienceNanoparticleImogoliteNanotechnology02 engineering and technologyMesoporous silica010402 general chemistry021001 nanoscience & nanotechnologySilicon Dioxide01 natural sciencesControlled release0104 chemical sciencesNanomaterialsNanofiberDelayed-Action PreparationsDrug deliveryClayHumansNanoparticlesAdsorption0210 nano-technologyMesoporous materialPorosityTherapeutic delivery
researchProduct

Amphiphilic HPMA-LMA copolymers increase the transport of Rhodamine 123 across a BBB model without harming its barrier integrity.

2012

Abstract The successful non-invasive treatment of diseases associated with the central nervous system (CNS) is generally limited by poor brain permeability of various developed drugs. The blood–brain barrier (BBB) prevents the passage of therapeutics to their site of action. Polymeric drug delivery systems are promising solutions to effectively transport drugs into the brain. We recently showed that amphiphilic random copolymers based on the hydrophilic p(N-(2-hydroxypropyl)-methacrylamide), pHPMA, possessing randomly distributed hydrophobic p(laurylmethacrylate), pLMA, are able to mediate delivery of domperidone into the brain of mice in vivo. To gain further insight into structure–propert…

Drug CarriersPharmaceutical SciencePolymer architectureBiological TransportPharmacologyBlood–brain barrierRhodamine 123Models BiologicalPermeabilityCell Linechemistry.chemical_compoundmedicine.anatomical_structurechemistryTranscytosisIn vivoBlood-Brain BarrierNanoparticles for drug delivery to the brainAmphiphilemedicineHumansMethacrylatesRhodamine 123Barrier functionFluorescent DyesJournal of controlled release : official journal of the Controlled Release Society
researchProduct

Core-Shell Arginine-Containing Chitosan Microparticles for Enhanced Transcorneal Permeation of Drugs

2019

Chitosan oligosaccharide (C) was functionalized with L-arginine (A) and short hydrocarbon chains (C-8) to design an amphiphilic copolymer, henceforth CAC(8), leading to microparticles (MPs) consisting of an arginine-decorated hydrophilic shell and inner hydrophobic domains allowing the encapsulation of high amount hydrophobic drugs such as sorafenib tosylate (>10% w/w). L-arginine side chains were selected in order to impart the final MPs enhanced transcorneal penetration properties, thus overcoming the typical biological barriers which hamper the absorption of drugs upon topical ocular administration. The mucoadhesive properties and drug release profile of the CAC(8) MPs (CAC(8)-MPs) were …

Drug3003congenital hereditary and neonatal diseases and abnormalitiesArginineSwinemedia_common.quotation_subjectamphiphilic copolymerPharmaceutical ScienceL-arginineAdministration Ophthalmic02 engineering and technologyArginine030226 pharmacology & pharmacyCorneaChitosan03 medical and health scienceschemistry.chemical_compoundDrug Delivery Systems0302 clinical medicineMucoadhesionSide chainAnimalsskin and connective tissue diseasesProtein Kinase Inhibitorsmedia_commonMucin-3microparticlesDrug CarriersMucinnutritional and metabolic diseasesSorafenibPermeation021001 nanoscience & nanotechnologyCombinatorial chemistryBioavailabilityDrug LiberationmicroparticlechemistrySettore CHIM/09 - Farmaceutico Tecnologico Applicativoocular administrationchitosan0210 nano-technologymucoadhesion
researchProduct

Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis

2021

Recently, rapamycin (Rapa) represents a potential drug treatment to induce regression of atherosclerotic plaques

DrugBiodistributionmedia_common.quotation_subjectPharmaceutical ScienceExcipientNanoparticlelcsh:RS1-44102 engineering and technologyPharmaceutical formulationArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compoundPhosphatidylcholinemedicine030304 developmental biologymedia_commonKOdia-PC0303 health sciencesrapamycin (Rapa)technology industry and agriculture021001 nanoscience & nanotechnologyIn vitromacrophage targetingpolymeric nanoparticleschemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPolycaprolactoneBiophysicsatherosclerosis0210 nano-technologymedicine.drugPharmaceutics
researchProduct

Lipid Nanoparticles for Drug Targeting to the Brain

2012

In this chapter, the main production methods of lipid nanostructures such as solid lipid nanoparticles and nanostructured lipid carriers, and their application are described. In particular, we describe the strategies commonly used to obtain lipid nanoparticles to overcome the blood-brain barrier (BBB) for the treatment of several brain diseases. The use of these carriers as targeted drug delivery systems is associated with many advantages that include excellent storage stability, easy production without the use of any organic solvent, the possibility of steam sterilization and lyophilization, and large scale production. They exhibit good stability during long-term storage, consist of physio…

DrugChemistrymedia_common.quotation_subjectOrganic solventNanoparticleNanotechnologySteam sterilizationTargeted drug deliverySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNanoparticles for drug delivery to the brainGenerally recognized as safeSolid lipid nanoparticlesolid lipid nanoparticles blood brain barriermedia_common
researchProduct

Immunotoxicity of Therapeutic Antibodies and Nanoparticles.

2020

Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining…

DrugCytotoxicity ImmunologicDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectImmunologyContext (language use)BioengineeringMonoclonal antibodyAntibodiesTargeted therapyImmunomodulationImmune systemImmunology and AllergyMedicineAnimalsHumansAdverse effectmedia_commonbusiness.industryImmunosuppressionTolerabilityDrug DesignImmune SystemImmunologyNanoparticlesbusinessCritical reviews in immunology
researchProduct

Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy.

2021

Gene-directed enzyme prodrug therapy (GDEPT) has been intensively studied as a promising new strategy of prodrug delivery, with its main advantages being represented by an enhanced efficacy and a reduced off-target toxicity of the active drug. In recent years, numerous therapeutic systems based on GDEPT strategy have entered clinical trials. In order to deliver the desired gene at a specific site of action, this therapeutic approach uses vectors divided in two major categories, viral vectors and non-viral vectors, with the latter being represented by chemical delivery agents. There is considerable interest in the development of non-viral vectors due to their decreased immunogenicity, higher…

DrugDendrimersmedicine.medical_treatmentmedia_common.quotation_subjectGenetic VectorsPharmaceutical ScienceEnzyme TherapyComputational biologyReviewdendrimerdelivery vehiclesAnalytical ChemistryTargeted therapyViral vectornon-viral vectorQD241-441DendrimerGDEPTDrug DiscoverymedicineAnimalsHumansProdrugsPhysical and Theoretical ChemistryGenemedia_commonchemistry.chemical_classificationGDEP therapyImmunogenicityOrganic ChemistrytransgeneGene Transfer TechniquesGenetic TherapyProdrugtargeted therapyEnzymesEnzymechemistrygene delivery systemChemistry (miscellaneous)Molecular MedicineNanoparticlesMolecules (Basel, Switzerland)
researchProduct

The zebrafish embryo as an in vivo model for screening nanoparticle-formulated lipophilic anti-tuberculosis compounds.

2021

ABSTRACT With the increasing emergence of drug-resistant Mycobacterium tuberculosis strains, new and effective antibiotics against tuberculosis (TB) are urgently needed. However, the high frequency of poorly water-soluble compounds among hits in high-throughput drug screening campaigns is a major obstacle in drug discovery. Moreover, in vivo testing using conventional animal TB models, such as mice, is time consuming and costly, and represents a major bottleneck in lead compound discovery and development. Here, we report the use of the zebrafish embryo TB model for evaluating the in vivo toxicity and efficacy of five poorly water-soluble nitronaphthofuran derivatives, which were recently id…

DrugIn vivo efficacyTuberculosismedicine.drug_classmedia_common.quotation_subjectAntibioticsAntitubercular AgentsNeuroscience (miscellaneous)Medicine (miscellaneous)Anti-tuberculosis drugsPharmacologyBiologyGeneral Biochemistry Genetics and Molecular BiologyMycobacterium tuberculosisMiceImmunology and Microbiology (miscellaneous)In vivoZebrafish as a Disease ModelmedicineAnimalsTuberculosisZebrafishmedia_commonIn vivo toxicityDrug discoveryMycobacterium tuberculosismedicine.diseasebiology.organism_classificationIn vitroZebrafish tuberculosis modelDrug developmentNanoparticlesResearch Article
researchProduct

PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen.

2018

The oral controlled release (CR) formulations have become more important in recent years. Among them, the polymeric nanoparticles have been thoroughly studied during the last decades, consequently they are extensively employed for a broad range of applications and drugs. The objective of this research was to develop polymeric nanoparticles (NPs) of ibuprofen with poly(lactic-co-glycolic) acid (PLGA) as polymer, and to test their applicability for oral CR formulations development. Different proportions of drug/polymer were employed to develop the ibuprofen NPs and their in vitro release profiles were analysed. The in situ segmental permeability of ibuprofen was tested in Wistar rat and demon…

DrugMaleColonPolymersmedia_common.quotation_subjectPharmaceutical ScienceIbuprofen02 engineering and technologyAbsorption (skin)030226 pharmacology & pharmacyPermeability03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIn vivomedicineAnimalsLactic AcidRats Wistarmedia_commonchemistry.chemical_classificationDrug CarriersChromatographyorganic chemicalstechnology industry and agriculturePolymer021001 nanoscience & nanotechnologyIbuprofenControlled releaseRatsPLGAchemistryIntestinal AbsorptionPermeability (electromagnetism)Delayed-Action PreparationsNanoparticles0210 nano-technologyPolyglycolic Acidmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

2007

An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube(R), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug deliv…

DrugMalemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalDosage formPharmacokineticsFenofibrateSuspensionsSolid lipid nanoparticlemedicineAnimalsComputer SimulationTissue DistributionSolubilityRats Wistarmedia_commonHypolipidemic AgentsFenofibrateChemistryLipidsBioavailabilityRatsSolubilityDrug deliveryNanoparticlesmedicine.drugAdvanced drug delivery reviews
researchProduct